The Anthem Biosciences IPO has launched and is drawing strong attention. The IPO comes with a high grey market premium (GMP), strong anchor investor backing, and healthy financials. If you’re thinking about applying or just want to understand the buzz, this blog will cover it all.
What Is Anthem Biosciences?
Anthem Biosciences is a Bengaluru-based company. It works in pharma research and manufacturing. It helps other drug companies with R&D, testing, and large-scale production.
It is known as a CRDMO, which stands for Contract Research, Development, and Manufacturing Organization. In simple words, it helps make active ingredients, enzymes, vitamins, and other drug parts used in final products.
The company was started in 2007 and serves clients across India, the US, and other countries. Over time, it has grown in both size and revenue.
Anthem Biosciences IPO – Key Details
The Anthem Biosciences IPO opened on July 14, 2025, and will close on July 16, 2025.
Here are the key facts:
- IPO Size: ₹3,395 crore
- Offer Type: 100% Offer-for-Sale (OFS)
- Price Band: ₹540 to ₹570 per share
- Lot Size: 26 shares
- Minimum Investment: ₹14,820 (at upper band)
- Listing Date: Likely on July 21, 2025
- Exchanges: BSE and NSE
Since it’s an OFS, the company itself will not get new money. The shares are being sold by current shareholders.
Anthem Biosciences IPO GMP – What It Shows
The Anthem Biosciences IPO GMP is around ₹97 as of Day 1. That means grey market buyers are offering ₹97 more than the IPO price. If you take the upper band of ₹570, the expected listing price is about ₹667.
A GMP of nearly 17% is strong. It shows demand is good. But remember, GMP is unofficial. It can go up or down before the listing. Still, a high GMP usually means a good chance of listing gains.
Investors often track GMP to guess listing price. It helps decide whether to apply for short-term profit.
Financial Snapshot – How the Company Is Doing
Here are Anthem’s key financial numbers:
- Revenue FY24: ₹1,844 crore
- Profit (PAT) FY24: ₹451 crore
- EBITDA Margin: 37%
- Growth: Revenue and profit both up from last year
The company makes money and shows profit growth. It has low debt and strong operating margins.
But one risk is that more than 70% of revenue comes from just five clients. If one leaves, it can hurt income.
Anchor Investor Support – Who’s Interested?
Before the IPO opened, Anthem raised ₹1,016 crore from anchor investors. That means big names bought shares early.
Top anchor names include:
- ADIA
- Amundi
- Eastspring
- PineBridge
- HSBC
- Goldman Sachs
Strong anchor demand shows trust in the company. When large funds buy early, it often gives retail investors more confidence.
Manufacturing and Capacity
Anthem has several production units. All are located in Karnataka. The company uses these for making APIs, enzymes, and more.
Here’s a quick view:
- Unit 1 & 2: Total 270KL synthesis and 142KL fermentation capacity
- Unit 3: Recently added with ₹600 crore investment
- Unit 4: In planning; will be the biggest of all units
The new units will help boost production. This could increase revenue in the next few years.
Why Is Anthem Launching This IPO?
Since the IPO is an OFS, the company isn’t raising fresh money. So why go public?
Here’s why:
- Existing shareholders want to sell part of their stake
- Public listing improves brand and trust
- Listing helps raise money easily in the future if needed
Though the company won’t get funds from this issue, its growing capacity shows it plans for expansion.
Peer Comparison – Who Are the Rivals?
Anthem is not alone in this space. It has rivals like:
- Syngene International
- Divi’s Laboratories
- Suven Pharma
Compared to these, Anthem has better growth but less size. Syngene and Divi’s are older and more established. Still, Anthem’s niche in fermentation gives it an edge.
At the IPO price, Anthem’s P/E is around 70–71. That’s higher than peers, which may worry some investors. But strong margins and growth help justify it.
IPO Subscription and Timeline
Here’s the full timeline of the IPO:
- Open Date: July 14
- Close Date: July 16
- Allotment Date: July 17
- Refunds Start: July 18
- Shares in Demat: July 18
- Listing Date: July 21 (Expected)
Retail investors can apply until July 16. You’ll know by July 17 if you got shares. If not, refunds will be processed the next day.
Analyst Ratings and Public Sentiment
Broker views on the Anthem Biosciences IPO are mostly positive.
Here’s what some say:
- SBI Securities: Strong business, good for long-term
- Anand Rathi: Solid niche, high entry barrier
- Canara Bank Securities: Good profit margins, safe balance sheet
- Choice Broking: High valuation but justified
- Swastika: Suggests “Subscribe” for both short and long term
Most rate it a “subscribe”. The reason: strong numbers, expansion, global clients, and demand in the IPO.
Social media sentiment also looks good. Many retail investors are applying based on GMP.
Should You Apply to Anthem Biosciences IPO?
This depends on your goal.
If you want short-term gains, GMP of ₹97 is a green signal. Listing gains are likely.
If you want to hold long-term, think about these:
Pros:
- Good revenue growth
- Profit-making
- Solid EBITDA margin
- Growing production units
- Global clients
Risks:
- High customer concentration
- High valuation (P/E 70+)
- No fresh funds for the company
If you’re okay with these risks, it can be a strong long-term bet.
Final Thoughts – Is Anthem IPO Worth It?
The Anthem Biosciences IPO has everything investors look for — profit, growth, anchor backing, and high GMP. GMP near 17% shows good market interest. The company’s strong numbers add to the trust.
If you’re looking for listing gains, this IPO is worth applying for. If you’re a long-term investor, make sure you’re fine with the high price and client risk.
Overall, it’s a well-received IPO in the pharma space. Keep track of allotment on July 17 and watch the listing price on July 21.
